Singapore markets open in 4 hours 59 minutes
  • Straits Times Index

    3,247.76
    -35.59 (-1.08%)
     
  • S&P 500

    4,402.08
    -8.05 (-0.18%)
     
  • Dow

    34,536.78
    +172.28 (+0.50%)
     
  • Nasdaq

    13,747.18
    -107.95 (-0.78%)
     
  • BTC-USD

    37,168.69
    +1,166.00 (+3.24%)
     
  • CMC Crypto 200

    846.36
    +25.77 (+3.14%)
     
  • FTSE 100

    7,371.46
    +74.31 (+1.02%)
     
  • Gold

    1,852.90
    +11.20 (+0.61%)
     
  • Crude Oil

    85.43
    +2.12 (+2.54%)
     
  • 10-Yr Bond

    1.7810
    +0.0460 (+2.65%)
     
  • Nikkei

    27,131.34
    -457.03 (-1.66%)
     
  • Hang Seng

    24,243.61
    -412.85 (-1.67%)
     
  • FTSE Bursa Malaysia

    1,508.91
    -12.95 (-0.85%)
     
  • Jakarta Composite Index

    6,568.17
    -86.99 (-1.31%)
     
  • PSE Index

    7,288.21
    +35.57 (+0.49%)
     

Xencor to Present at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • XNCR

MONROVIA, Calif., November 19, 2021--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:

  • Piper Sandler 33rd Annual Virtual Healthcare Conference
    Presentation Available: Monday, November 22, 2021, 10:00 a.m. EST / 7:00 a.m. PST

  • Evercore ISI 4th Annual HealthconX Conference
    Presentation Date: Wednesday, December 1, 2021, 1:00 p.m. EST / 10:00 a.m. PST

Webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. A replay of the live Evercore ISI presentation will be posted on the Xencor website approximately one hour after the live event. Both presentations will be available on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005693/en/

Contacts

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting